To improve financial access to CAR T-Cell therapy in India
Immuneel Therapeutics announced strategic partnerships with Impact Guru, a leading healthcare crowdfunding platform, and CarePal Money, a healthcare-focussed lending marketplace. The collaborations aim to significantly improve financial access to CAR T-cell therapy for patients across diverse socio-economic backgrounds.
Impact Guru will enable patients and families to raise funds through its digital crowdfunding platform, mobilising community support via donation campaigns and awareness drives backed by a donor network of over 50 lakh contributors.
CarePal Money will facilitate structured credit solutions by connecting eligible patients with its network of NBFC partners, offering tailored loan and financing options for medical treatment.
Immuneel Therapeutics will continue to deliver globally benchmarked CAR T-cell therapies in India, while working closely with both partners to ensure timely financial support alongside clinical care.
Amit Mookim, Board Director and Chief Executive Officer, Immuneel Therapeutics, said, “Scientific innovation alone does not transform cancer care. Real impact comes when breakthrough therapies reach patients who need them most, regardless of financial circumstance. Through our partnerships with Impact Guru and CarePal Money, we are building a more holistic access ecosystem that combines clinical excellence with financial enablement, aligned with India’s ambitions in advanced therapeutics and universal health coverage.”
Piyush Jain, Co-Founder and CEO, CarePal Group and Impact Guru, added, “Healthcare innovation needs inclusive financing models. This partnership creates a dual pathway: patients can mobilise community support through Impact Guru’s crowdfunding platform while also accessing structured credit through CarePal Money’s NBFC partners. Together, this offers both flexibility and financial security at a critical time.”
Sahil Lakshmanan, Chief Business Officer, CarePal Money, said, “As medical innovation advances, healthcare financing must evolve alongside it. By institutionalising credit access for advanced therapies through our NBFC partnerships, we aim to reduce financial shock for families and support continuity of care.”
